Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Laserscope (NASDAQ LSCP) -- Ignore unavailable to you. Want to Upgrade?

To: Dick Martin who wrote (253)	3/14/1999 10:17:00 AM
From: Bob Davis	Read Replies (1) \| Respond to of 314

Since Laserscope (NASDAQ:LSCP) is a participant in the dermatological laser industry, it has been included in a study of this segment published in The Napeague Letter. Although LSCP has announced plans to introduce several new products aimed at this segment in 1999, its most promising opportunities appear to lie in the area of "photodynamic therapy". After a number of years of unprofitable performance, LSCP management announced a restructuring program designed to improve operating results and return the company to profitability. However, results are not expected from this effort until later this year. The Napeague Letter is watching for certain indicators, which might signal the return to revenue and earnings growth, including indications that its move into "photodynamic therapy" is becoming successful, and evidence that the restructuring is having an impact, leading to an improvement in operating results. Additional information about LSCP, including graphics and charts, can be found at napeague.com The Napeague Letter plans to continue to track LSCP to watch for signs that a turnaround is taking place. Bob Davis The Napeague Letter